Stay updated on Fisogatinib in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision tag updated to v3.4.2 and an older notice (v3.4.1) was removed. These changes pertain to site maintenance and do not alter study details or eligibility information presented on the page.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a site-wide funding notice about a lapse in government funding and updated to revision v3.4.1. The notice warns that site information may not be up to date and points to current operating status resources.SummaryDifference0.3%

- Check28 days agoChange DetectedUI updates include showing the glossary, changing the QC-status label to 'Last Update Submitted that Met QC Criteria', correcting capitalization for 'No FEAR Act Data', and updating the revision from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check35 days agoChange DetectedA large set of MeSH terms, keywords, and historical metadata were removed from the page. The essential study description and location information appear unchanged.SummaryDifference16%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No substantive changes to study content or listings.SummaryDifference0.0%

- Check64 days agoChange DetectedExpanded the study's Locations with new sites across the United States and China and removed several earlier location groupings; a revision tag (Revision: v3.3.3) was added.SummaryDifference2%

Stay in the know with updates to Fisogatinib in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page.